Germany Diabetes Therapeutics Market Report 2022 to 2030

Germany Diabetes Therapeutics Market Analysis

$ 3999

German diabetes therapeutics market is expected to grow from $5.26 Bn in 2022 to $9.67 Bn in 2030 with a CAGR of 7.9% for the forecasted year 2022-30. The growing prevalence of diabetes and various other factors like obesity and lack of exercise are contributing to the expansion of the market. The German diabetes therapeutics market is segmented by type, application, drug, route of administration, and distribution channel. Esteve Pharmaceuticals, Celares, and Salix Pharmaceuticals are the major players in the German diabetes therapeutics market.

ID: IN10DEPH036 CATEGORY: Pharmaceuticals GEOGRAPHY: Germany AUTHOR: Dr. Parul Choudhary

Buy Now

Germany Diabetes Therapeutics Market Executive Analysis

German diabetes therapeutics market size is at around $5.26 Bn in 2022 and is projected to reach $9.67 Bn in 2030, exhibiting a CAGR of 7.9% during the forecast period. Jens Spahn, the minister of health, is asking for an increase of $31 Bn in the 2022 budget. This year, the central government will spend a total of $543 Bn. For the years 2022 and 2023, the Finance Ministry recently received requests totaling about $54 Bn for the fields of health, care, and pensions. In 2023, the contributions for more than 57 Mn GKV members will be considerably increased.

At least 7.2 % of the population in Germany currently has diabetes, the majority of which is type 2 diabetes, based on the estimate. Over the next 20 years, there will be a significant rise in the number of diabetics. Up to 12 Mn individuals in Germany could have type 2 diabetes in 20 years, according to researchers at the Robert Koch Institute (RKI) in Berlin and the German Diabetes Centre (DDZ) in Düsseldorf. From 2015 to 2040, this would represent a rise of up to 77%.

A novel hormone combination has been created by a research team from Helmholtz Munich, the German Center for Diabetes Research (DZD), and Novo Nordisk to treat type 2 diabetes in the future. A new and extremely effective medication has been created by combining the blood sugar-lowering properties of the drugs tesaglitazar and GLP-1 (glucagon-like peptide-1). The benefit is that Tesaglitazar only penetrates tissue that contains GLP-1 receptors thanks to the GLP-1 and Tesaglitazar combination. This increases the impacts on sugar metabolism while lessening the side effects of tesaglitazar. Animal studies using the novel medication have already been completed successfully. Tesaglitazar helps type 2 diabetic people with their glucose and fat metabolism. It works to improve insulin sensitivity by interacting with two receptors in the cell nucleus. The novel medication enhances sugar metabolism and glucose tolerance. The next step for the researchers is to find out if this medication can also be used to treat type 2 diabetes in people and if biochemical adjustments can be made to improve the efficacy of this novel combination treatment.

Germany Diabetes Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers

The German Diabetes Center (DDZ) estimates that at least 7.2% of the population in Germany presently has diabetes, and that number will rise significantly over the next 20 years. Obesity, an unhealthy diet, and lack of exercise are the primary causes of the rise in newly identified Type 1 and Type 2 diabetes cases. Healthcare spending and the quickly rising incidence and prevalence of diabetic patients are indicators of the growing use of diabetic care medications. These mentioned factors are responsible for the expansion of the German diabetes therapeutics market.

Market Restraints

The cost of treating diabetes can be high, especially for more recent methods of therapy. Patients may find it difficult to pay for care as a result, and the use of novel treatments may be hampered. Strict regulations apply to the German diabetes therapeutics market, especially regarding drug approval and cost. This can limit a company's ability to establish prices and make it difficult for them to introduce new products to the market thus limiting the development of the German diabetes therapeutics market.

Competitive Landscape

Key Players

PharmaLex (DEU)
Pensatech Pharma (DEU)
NextPharma (DEU)
Esteve Pharmaceuticals (DEU)
Celares (DEU)
Salix Pharmaceuticals
Takeda Pharmaceutical
Ji'Nan Orgachem Pharmaceutical
Shihuida Pharma

Healthcare Policies and Regulatory Landscape

One of the primary responsibilities of the Federal Institute for Drugs and Medical Devices (BfArM) is the authorization of pharmaceuticals under the authority of the Medicinal Products Act (Arzneimittelgesetz, AMG). The health benefit, efficacy, safety, and pharmaceutical quality of the medicinal products, are examined during these licensing processes. Additionally, the BfArM performs crucial duties in relation to drug licensure on a European level. The BfArM either registers homoeopathic medications without a declaration of indications or licenses them with indications. Rare side effects that are not always detectable during the clinical studies needed for licensing may be discovered if a medicinal product is used by a large number of patients after receiving marketing authorization. Such reports of negative drug reactions are gathered and evaluated by the pharmacovigilance section. The BfArM acts accordingly to guarantee patient protection based on this.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Diabetes Therapeutics Segmentation

By Type (Revenue, USD Billion):

Diabetes 1
Diabetes 2

By Application (Revenue, USD Billion):

Preventive
- Prediabetes
- Nutrition
- Obesity
- Lifestyle Management
Treatment/Care
- Diabetes
- Smoking Cessation
- Musculoskeletal Disorders
- Central Nervous System Disorders
- Cardiovascular Disease
- Medication Adherence
- Chronic Respiratory Disorders
- Gastrointestinal Disorders
- Rehabilitation
- Substance Use Disorders & Addiction Management

By Drug (Revenue, USD Billion):

Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drug
Combination Drug

By Route of Administration (Revenue, USD Billion):

Oral
Subcutaneous
Intravenous

By Distribution Channel (Revenue, USD Billion):

Online Pharmacies
Hospital Pharmacies
Retail Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.

We value your inquiry and offer free customization with every report to fulfil your exact research needs.

Yes, I have read the privacy policy

Esteve Pharmaceuticals, Celares, and Salix Pharmaceuticals are the major players in the Germany diabetes therapeutics market.

The Germany diabetes therapeutics market is expected to grow from $5.26 Bn in 2022 to $9.67 Bn in 2030 with a CAGR of 7.9% for the forecasted year 2022-2030.

The German diabetes therapeutics market is segmented by type, application, drug, route of administration, and distribution channel.